- Home
- NOW vs GILD Comparison
NOW vs GILD Comparison
Compare NOW & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NOW | GILD |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.2B | 154.7B |
| IPO Year | 2012 | 1992 |
Fundamental Metrics
Financial Performance| Metric | NOW | GILD |
|---|---|---|
| Price | $143.53 | $121.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 21 |
| Target Price | ★ $220.45 | $128.67 |
| AVG Volume (30 Days) | ★ 10.1M | 6.3M |
| Earning Date | 01-28-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.62% |
| EPS Growth | 28.67 | ★ 6514.05 |
| EPS | 1.65 | ★ 6.42 |
| Revenue | $12,667,000,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $21.67 | $3.63 |
| Revenue Next Year | $18.42 | $3.10 |
| P/E Ratio | $88.40 | ★ $18.79 |
| Revenue Growth | ★ 21.05 | 2.79 |
| 52 Week Low | $135.73 | $88.57 |
| 52 Week High | $239.62 | $128.70 |
Technical Indicators
Market Signals| Indicator | NOW | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 9.13 | 47.41 |
| Support Level | $145.64 | $116.88 |
| Resistance Level | $152.11 | $125.11 |
| Average True Range (ATR) | 3.67 | 2.67 |
| MACD | 6.35 | -0.23 |
| Stochastic Oscillator | 9.56 | 41.98 |
Price Performance
Historical ComparisonAbout NOW ServiceNow Inc.
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).